Regenicin Current Cash

The latest current cash for RGIN is $0 as of September 2023. That compares with $15K in the prior-year period — down 100.0% year over year. Investors often review this figure alongside Regenicin's historical trend and sector peers before judging valuation or financial health.

Over the past year, RGIN's current cash moved from $15K to $0 — a 100.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Regenicin's operating scale or balance-sheet position.

A current cash figure of $0 for RGIN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting RGIN's current cash ($0), review year-over-year change from $15K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Regenicin's current cash against similar Industrials names. You can also browse sector and industry screens on Stockcircle for a broader set of Industrials companies and their key multiples and fundamentals.